Melanoma Global Clinical Trials Review, H2, 2017
December 2017
1302
About the Report
About the Report
Melanoma Global Clinical Trials Review, H2, 2017
Summary
GlobalData's clinical trial report, "Melanoma Global Clinical Trials Review, H2, 2017" provides an overview of Melanoma clinical trials scenario. This report provides top line data relating to the clinical trials on Melanoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Products
Companies
Bristol-Myers Squibb Co
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Novartis AG
GlaxoSmithKline Plc
AstraZeneca Plc
Pfizer Inc
Sarah Cannon Research Institute LLC
Eisai Co Ltd
Amgen Inc
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Melanoma to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Melanoma to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Melanoma Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Melanoma
Dec 13, 2017: Enrollment of First Patient in Investigator-Initiated Clinical Trial for Telomelysin (OBP-301)-pembrolizumab combination therapy
Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews
Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma
Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017
Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO
Nov 07, 2017: Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
Nov 03, 2017: Adaptimmune to Present Update On MAGE-A4 Multi-tumor Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Oct 30, 2017: CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics
Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute
Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology 130
Secondary Research 130
About GlobalData 130
Contact Us 130
Disclaimer 130
Source
List of Figure
List of Figures
Melanoma Therapeutics, Global, Clinical Trials by Region (%), 2017*
Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Melanoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017*
Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017*
Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Melanoma Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
GlobalData Methodology 130
List of Table
List of Tables
Melanoma Therapeutics, Global, Clinical Trials by Region, 2017*
Melanoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Melanoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Melanoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Melanoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Melanoma Therapeutics Clinical Trials, North America, Top Countries, 2017*
Melanoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Melanoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Melanoma to Oncology Clinical Trials, G7 Countries (%), 2017*
Melanoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Melanoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Melanoma to Oncology Clinical Trials, E7 Countries (%), 2017*
Melanoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Melanoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Melanoma Therapeutics, Global, Clinical Trials by Phase, 2017*
Melanoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Melanoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Melanoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Melanoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Melanoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Melanoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Melanoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Melanoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.